Research programme: cancer immunotherapeutics - Formula Pharmaceuticals

Drug Profile

Research programme: cancer immunotherapeutics - Formula Pharmaceuticals

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Formula Pharmaceutical
  • Class Immunotherapies
  • Mechanism of Action Cytokine-induced killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 22 Feb 2016 Formula Pharmaceuticals and Rockland Immunochemicals enter into a collaboration agreement to develop cytokine induced killer cell based CAR immunotherapies
  • 22 Feb 2016 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top